Join the club for FREE to access the whole archive and other member benefits.

Matthew Scholz

Founder and Chief Executive Officer at Oisín Biotechnologies

Matthew Scholz is the founder and Chief Executive Officer of Immusoft, a biotech start-up firm that is developing a breakthrough technology that will turn a patient’s B cells into miniature drug factories. Longer term, this technology has the potential to transform the landscape of biomedicine.

 matthewscholz

See also: Company Oisin Biotechnologies - Drug development company focused on the senolytic technology to fight age-related diseases

Details last updated 15-May-2020

Matthew Scholz News

Oisín Biotechnologies' gene therapy may be available in the next 5 years

Longevity Technology - 22-Jan-2021

Results in mice suggest that it can increase median lifespan in humans by 15 years

Read more...

Nature Biotechnology reviews the state of play of senolytics

Nature Biotechnology - 12-Nov-2020

In August, Unity announced that its lead drug candidate had failed to beat a placebo in reducing ...

Read more...

OncoSenX raises more funds for cancer therapy, plans for clinical trial

GeekWire - 11-May-2020

Allowing developments on tech that will kill cancer based on their genetics

Read more...

Oisín made it to top 10 breakthrough technologies of 2020

Business Wire - 26-Feb-2020

Will begin clinical trials after completing pre-clinical studies

Read more...